Atogepant is an oral anti-migraine drug that blocks the calcitonin gene-related peptide (CGRP) receptor.¹ It was previously evaluated in the phase 3, randomized, double-blind, placebo-controlled trials ELEVATE and PROGRESS for the prevention of episodic migraine (EM) or chronic migraine (CM), respectively.¹

Obstructive sleep apnea (OSA) is a modifiable cause of hypertension but is often underdiagnosed.1 Patients with hypertension are at a higher risk for cardiac and cerebrovascular diseases and are thus recommended to undergo screening and treatment of OSA.1 While the continuous positive airway pressur

In patients with type 2 diabetes (T2D), albuminuria is an early clinical marker of chronic kidney disease (CKD) and is associated with an increased risk of CKD progression and cardiovascular (CV) events.1 Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has exhibited efficacy in si

Migraine is a neurologic disorder characterized by recurrent attacks of pulsating headache that may be accompanied by an array of sensory symptoms or even cognitive dysfunction. Traditional treatments for migraine prevention are rarely disease-specific with unsatisfactory effectiveness and tolera

Migraine is a neurological disease caused by the release of inflammatory substances in the brain that triggers headache.¹ There is an unmet need to develop suitable treatment options for migraine patients with aura.² Recently, the use of erenumab, the first-in-class anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, has demonstrated significant reduction in migraine frequency and improved safety in patients with migraine.^2,3

Although hypertension (HTN) typically has no symptoms, it has serious health consequences. For instance, according to a study conducted in the United States (US), the rate of deaths related to hypertension have risen by 72% and 20% in rural and urban areas, respectively. The details of the study and